Bill > HB505

This bill introduces new requirements for retail pharmacies and wholesale drug distributors to improve access to buprenorphine, a medication used to treat opioid use disorder. Under the bill, retail pharmacies that stock controlled substances must calculate and maintain a minimum daily stock of buprenorphine based on their average daily dispensing, ensuring they have enough medication to cover their typical needs plus three additional prescriptions (including at least one monoproduct and one combination product). Wholesale drug distributors are now required to report to the board of pharmacy any instances where they deny or delay buprenorphine orders from retail pharmacies, providing detailed information about such incidents. The department of health will analyze these reports and publish biannual reports on buprenorphine access, examining factors like geographic disparities, reasons for order denials, and the impact on treatment and health outcomes. The bill establishes penalties for non-compliance: retail pharmacies can face fines up to $2,500 for repeated violations, while wholesale drug distributors can be fined up to $10,000. The goal is to ensure more consistent availability of this critical medication for treating opioid use disorder and to create transparency in the drug distribution system.

Health and Social Services

https://www.nmlegis.gov/Legislation/Legislation?chamber=H&legtype=B&legno=505&year=25